 |
 |
 |
 |
 |
 |
 |
|
|
NCCN Breast Cancer Guidelines UpdateA presentation from the NCCN 12th Annual Conference: Clinical Practice Guidelines & Quality Cancer Care™ held in Hollywood, Florida, on March 16, 2007 Presenters Beryl McCormick, MD John H. Ward, MD Faculty Disclosure Statements Beryl McCormick, MD Dr. McCormick has disclosed that she has no financial interests, arrangements, or affiliations with the manufacturer of products and devices to be discussed in her presentation or who may financially support the educational activity. Dr. McCormick has indicated that her presentation will not include discussion of investigational or unlabeled uses of a product. John H. Ward, MD Dr. Ward has disclosed that he has financial interests, arrangements, or affiliations with the manufacturer of products and devices to be discussed in his presentation or who may financially support the educational activity. He has served as a paid consultant for Myriad Genetics, Inc. and the National Cancer Institute. Dr. Ward has indicated that his presentation will not include discussion of investigational or unlabeled uses of a product. Program Overview This presentation will focus on the rationale behind the latest changes to the NCCN Breast Cancer Guidelines, including the issues surrounding the use of MRI in the workup of patients with breast cancer. Guidelines for HER2 testing and the use of trastuzumab will also be discussed. Educational Objectives Following this activity, participants should be able to:
Intended Audience This educational activity is designed to meet the needs of physicians, nurses, and other clinical professionals who manage patients with cancer. Activity Instructions Continuing education credit will be awarded to participants who listen to the presentation and complete the evaluation. Participants should review the learning objectives and faculty disclosure statements prior to listening to a presentation in its entirety. You must be connected to the Internet in order to review and complete the evaluation form. A statement of credit will be electronically generated once you complete the evaluation form. To receive credit, this activity must be completed no later than May 14, 2008. There is no fee for participating in this activity. Accreditation Information Physicians The National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians. NCCN designates this educational activity for a maximum of 0.75 AMA PRA Category Nurses This activity is approved for 0.8 contact hours. National Comprehensive Cancer Network is an approved provider of continuing nursing education by the PA State Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. Approval as a provider refers to recognition of educational activities only and does not imply ANCC Commission on Accreditation or PA Nurses approval or endorsement of any product. Kristina M. Gregory, RN, MSN, OCN, is our nurse planner for this educational activity. Release date: May 14, 2007 Commercial Support Distribution supported by educational grants from AstraZeneca Pharmaceuticals LP, Abraxis Bioscience, Inc., and Genentech, Inc.
|
|
NCCN 1st Annual Forum: Innovative Diagnostics & Therapeutics in Cancer Care™ |
|
|
